United Therapeutics saw its IBD SmartSelect Composite Rating jump to 96 Tuesday, up from 91 the day before.
The new rating shows the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria.
United Therapeutics is not currently near a proper buy point. See if the stock goes on to form a new base and offer a new buying opportunity.
Looking For Winning Stocks? How To Invest In Both Bull And Bear Markets
The stock earns a 94 EPS Rating, which means its recent quarterly and longer-term annual earnings growth is outpacing 94% of all stocks.
Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.
The company reported a 42% earnings-per-share gain for Q4. It has now posted accelerating EPS growth for two consecutive quarters. Top line growth came in at 20%, down from 23% in the prior quarter.
United Therapeutics earns the No. 12 rank among its peers in the Medical-Biomed/Biotech industry group. Krystal Biotech, ADMA Biologics and Catalyst Pharmaceuticals are among the top 5 highly-rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
